Your function within the department
The NKI, located in Amsterdam, is the only comprehensive cancer center in The Netherlands. It is a well-organized and dynamic institute accommodating over 50 research groups and many advanced core facilities. It is an internationally renowned center covering fundamental, translational and clinical cancer research.
The Peeper lab has a strong track record in function-based genomics to aid the development of more durable clinical responses for cancer patients. We aim to identify specific tumor vulnerabilities for drug target and biomarker discovery and subsequently set up for clinical implementation, in close collaboration with our clinical colleagues.
To reach these goals, we develop and utilize in vitro and in vivo genome-wide functional perturbation screens for a better understanding of tumor heterogeneity and drug resistance as well as for the identification of factors amenable to pharmacologic intervention and predictive biomarkers. This is done for several cancer types including melanoma, lung and breast cancer. Given the advances made for immunotherapy, we have also established systems allowing for including immunological factors in our genetic screens. Candidate genes are assessed and ranked computationally and subsequently functionally validated in clinically relevant models, including patient-derived xenografts. Many of these elements will be covered in this project, aiming to develop novel treatment strategies.
We seek a highly ambitious postdoc. Experience in molecular cancer biology and/or immunology is recommended, as is a desire to translate your findings to the clinic.
Your career opportunities and terms of employment
You will be employed for a period of at least 3 years. The gross salary per month is € 3.363,- to € 3.774,- and depends on previous experience. The terms of employment will be in accordance with the CAO Hospitals.
For more information please contact prof. Daniel Peeper, Division of Molecular Oncology, Netherlands Cancer Institute, Amsterdam.
E-mail: email@example.com (don’t use this to apply).
- Kemper et al., BRAFV600E kinase domain duplication identified in therapy-refractory melanoma patient-derived xenografts. Cell Rep 2016
- Kemper et al., Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts. EMBO Mol Med 2015
- Kuilman, T. et al. CopywriteR: DNA copy number detection from off-target sequence data. Genome
- Possik et al., Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality
between hypoxia and DNA Damage Response inhibition. Cell Rep 2014
- Muller et al., Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Nature Comm 2014
- Kaplon et al., A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced
senescence, Nature 2013